U.S., March 21 -- ClinicalTrials.gov registry received information related to the study (NCT06887426) titled 'Cladribine Tablets as an Exit Therapy Strategy' on March 13.
Brief Summary: The objective of the study is to evaluate the effectiveness of CladT, in terms of disease stability and safety, as the last treatment option in ageing MS patients vs treatment continuation and discontinuation This observational study will use database from local cohorts (from France, Belgium, Switzerland). Patients included must meet the inclusion criteria: RRMS diagnosis for more than 10 years without secondary progression, no evidence of disease activity (no relapse, no new MRI lesion, no EDSS progression) for more than 5 years under a DMT, age>= 45-year-...